Abstract

Immunotherapy has improved outcomes for patients with blood cancers such as B-ALL. However, for patients with immune-cold cancers such as AML, currently available immunotherapies are less effective, likely due to lack of functional T cells and/or low expression of immune checkpoint proteins like PD-L1 . For these patients, development of an effective leukemia-targeting drug with immune-stimulating activity is required. We previously reported elevated PRMT9 levels in AML patient specimens, which enhanced leukemia cell proliferation by promoting RNA translation (Blood, 2021,138 [Supplement 1]: 358). Recently, our transcriptome profiling of AML lines revealed increased expression of interferon-stimulated genes (ISGs) after PRMT9-knockdown (KD), suggesting activation of innate immunity. To evaluate a potential PRMT9 function in anti-AML immunity, we transplanted either WT immunocompetent or Rag2-/- immunodeficient recipient mice with inducible Prmt9-KD or control MLL-AF9 (MA9) AML donor cells and monitored leukemia development by in-vivo bioluminescence Imaging. Unlike Rag2-/- recipients (overall survival <60 days), 5 of 7 WT recipients harboring Prmt9-KD AML survived the observation period (>120 days) and MA9 cells disappeared over time. To assess immune responses upon Prmt9 inhibition, we performed single-cell RNA-sequencing (scRNAseq) in BM and spleen cells from Prmt9-KD or control MA9-transplanted WT recipients (Fig. A). ScRNAseq analysis revealed that, relative to controls, Prmt9-KD induced T cell activation, based on increased T cell expression of Cd69, Gzmb and Ifng. After reanalyzing T cells at higher granularity based on levels of classical markers (e.g., Cd44, Sell, Fig. B, C), we observed reduced numbers of naïve T cells as well as increased effector/memory T cell subsets; increased numbers of cytotoxic T lymphocytes (CTLs) as well as decreased regulatory T cells (Tregs) subset (Fig. D). To validate T cell activation upon Prmt9 KD, we assessed an MA9/OVA transplant model (engineered with OVA to track antigen-specific T cells) and found that mice harboring Prmt9-KD MA9/OVA cells showed increased numbers of OVA-specific CD8+ T cells in BM tracked by flow cytometry after H-2Kb-OVA257-264 tetramer staining (Fig. E). Notably, scRNAseq analysis of multiple immune lineages in BM engrafted with Prmt9-KD MA9 cells revealed upregulation of Isg15, Cxcl10 and other ISGs. To confirm that type-I IFN responses mediate these effects, we implanted Prmt9-KD MA9 cells into WT or type-I IFN receptor KO (Ifnar1-/-) recipients and found that the survival advantage conferred by Prmt9-KD was lost in Ifnar1-/- recipients (Fig. F). Interestingly, Prmt9-KD in MA9 cells also increased expression of Isg15, Cxcl10 and other ISGs by Q-PCR assay, and the effect was blocked by cGAS deletion in MA9 cells, suggesting that Prmt9-KD activates cGAS-STING signaling. Finally, to determine whether Prmt9-KD phenotypes require tumor-intrinsic cGAS activity, we knocked out cGAS in Prmt9-KD MA9/OVA cells and implanted them into WT recipients. Relative to cGAS-WT controls, cGAS-KO in the presence of Prmt9-KD abolished survival advantages and cancer-specific T cell responses seen following Prmt9 KD in MA9/OVA cells (Fig. E). We also developed a potent new PRMT9 inhibitor (PRMT9i) based on our identified lead compound (Blood, 2021,138: 358). CyTOF analysis revealed that PRMT9i treatment ablated primary AML cells (CD34+CD45dim) and relatively increased T cell frequencies in co-cultures of immune cells with leukemia cells from primary AML specimens (n=3). However, PRMT9i anti-AML effects were significantly impaired by T cell depletion. Notably, CyTOF analysis revealed significantly upregulated PD-L1 levels in 2 of 3 (CD34+CD45dim) AML co-cultures after PRMT9i treatment (Fig. G), suggesting activation of the adaptive PD-1/PD-L1 axis, in agreement with the” unwanted negative effects” of cGAS-STING activation as others depicted. Accordingly, PRMT9i treatment of these 2 co-cultures combined with immune checkpoint inhibition (ICI, anti-PD1) synergistically eradicated primary AML cells (Fig. H) and promoted expansion of CD69+ and IFNγ+ CD8+ T cell subsets. Overall, we demonstrate that AML cell-derived PRMT9 regulates AML immune evasion, and that combining PRMT9i with ICIs could constitute a therapeutic strategy against PRMT9-proficient cancers like AML, in which single ICIs show limited efficacy. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call